Analyzing Iqvia (IQV) and Infinity Pharmaceuticals (INFI)

Iqvia (NYSE: IQV) and Infinity Pharmaceuticals (NASDAQ:INFI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Iqvia and Infinity Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iqvia $6.88 billion 3.03 $115.00 million $0.29 344.97
Infinity Pharmaceuticals $18.72 million 5.55 -$30.10 million ($1.14) -1.80

Iqvia has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Iqvia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Iqvia and Infinity Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iqvia 0.58% 12.60% 4.65%
Infinity Pharmaceuticals N/A -85.61% -59.80%

Insider and Institutional Ownership

95.8% of Iqvia shares are owned by institutional investors. Comparatively, 54.3% of Infinity Pharmaceuticals shares are owned by institutional investors. 6.4% of Iqvia shares are owned by company insiders. Comparatively, 6.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Iqvia has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Iqvia and Infinity Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iqvia 0 8 8 0 2.50
Infinity Pharmaceuticals 0 0 1 0 3.00

Iqvia presently has a consensus target price of $106.06, indicating a potential upside of 6.02%. Given Iqvia’s higher possible upside, equities analysts clearly believe Iqvia is more favorable than Infinity Pharmaceuticals.

Summary

Iqvia beats Infinity Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Iqvia Company Profile

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply